Fstar Therapeutics Stock Net Asset
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess FStar Therapeutics' long-term financial health and intrinsic value.
FStar |
FStar Therapeutics Company Net Asset Analysis
FStar Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current FStar Therapeutics Net Asset | 123.02 M |
Most of FStar Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FStar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, FStar Therapeutics has a Net Asset of 123.02 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all United States stocks is notably lower than that of the firm.
FStar Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FStar Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FStar Therapeutics could also be used in its relative valuation, which is a method of valuing FStar Therapeutics by comparing valuation metrics of similar companies.FStar Therapeutics is currently under evaluation in net asset category among its peers.
FStar Fundamentals
| Return On Equity | -0.61 | |||
| Return On Asset | -0.22 | |||
| Profit Margin | (2.11) % | |||
| Operating Margin | (1.62) % | |||
| Current Valuation | 98.23 M | |||
| Shares Outstanding | 21.98 M | |||
| Shares Owned By Insiders | 3.71 % | |||
| Shares Owned By Institutions | 44.90 % | |||
| Number Of Shares Shorted | 1.27 M | |||
| Price To Book | 2.13 X | |||
| Price To Sales | 5.47 X | |||
| Revenue | 21.17 M | |||
| Gross Profit | 21.17 M | |||
| EBITDA | (30.17 M) | |||
| Net Income | (31.28 M) | |||
| Cash And Equivalents | 35.57 M | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 9.61 M | |||
| Debt To Equity | 0.22 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | 2.59 X | |||
| Cash Flow From Operations | (27.27 M) | |||
| Short Ratio | 1.88 X | |||
| Earnings Per Share | (1.83) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 84 | |||
| Beta | -0.35 | |||
| Market Capitalization | 156.51 M | |||
| Total Asset | 123.02 M | |||
| Z Score | 9.6 | |||
| Net Asset | 123.02 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in FStar Stock
If you are still planning to invest in FStar Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FStar Therapeutics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |